Metabolic dysfunction-Associated Fatty liver Disease (MASLD) now dominates chronic liver disease (CLD) in Europe, surpassing viral hepatitis and alcohol-related causes, with a prevalence exceeding 25%. This rise is linked to escalating risk factors from unhealthy lifestyle. MASLD’s diverse clinical trajectory, including steatosis, NASH, cirrhosis and hepatocellular carcinoma, stems from varied underlying mechanisms. In particular, the inflammatory faced-non-alcoholic steatohepatitis (NASH) – heightens cardiovascular disease (CVD) risk, a leading cause of death in MASLD patients. Understanding MASLD progression and the liver-heart axis is crucial for effective management. This consortium will develop liver and heart computational models and virtual twins, offering insights into heart-liver functions across different stages of the disease.